Abstract P4-14-18: Phase I study of single-agent pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with ErbB2+ metastatic breast cancer
2009 ◽
Vol 15
(7)
◽
pp. 2552-2558
◽
2009 ◽
Vol 64
(6)
◽
pp. 1139-1148
◽
2017 ◽
Vol 164
(2)
◽
pp. 359-369
◽